ArticleScientific reports2025
Evaluation of nematode susceptibility and resistance to anthelmintic drugs with a WMicrotracker motility assay.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A practical miracidial motility assay for assessing Fasciola hepatica sensitivity to compounds in vitro.International journal for parasitology. Drugs and drug resistance · 2026Article
- Critical role of P-Glycoprotein-9 in ivermectin tolerance in nematodes.PLoS pathogens · 2026Article
- P-glycoprotein-9-mediated multidrug tolerance in Caenorhabditis elegans.Parasites & vectors · 2025Article
- Automated larval motility assays reveal links between eprinomectin treatment failure and drug resistance in Haemonchus contortus.Veterinary research · 2025Article
- Drug screens using the nematode Caenorhabditis elegans.Genetics · 2025Review
- Phenotypic Screening of HPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Grazing ruminants suffer from various helminth infections particularly those caused by gastrointestinal nematode (GIN) parasites, which have a considerable impact on their welfare and productivity. To treat these infections, the intensive use of macrocyclic lactone (ML) anthelmintics has led to the emergence of drug-resistant parasite populations worldwide. The standard method for detecting resistance, the Faecal Egg Count Reduction Test (FECRT), is susceptible to misinterpretation, leading to flawed management decisions that undermine parasite control efforts. Thus, there is a pressing need for robust resistance detection methods in field parasites. We investigated the potential of the WMicrotracker motility assay (WMA), previously unexplored in ML resistance assessment. The assay first compared ivermectin (IVM) susceptibility among wild-type Bristol N2 (N2B), IVM-selected (IVR10), and nhr-8 loss-of-function (AE501; nhr8(ok186)) Caenorhabditis elegans strains. Dose-response curves indicated that IVR10 had a 2.12-fold reduction in sensitivity to IVM compared to N2B. Additionally, cross-resistance assessment showed that IVR10 exhibited decreased sensitivity to moxidectin (MOX) and eprinomectin (EPR) relative to N2B. Further investigation conducted on Haemonchus contortus revealed significant differences in drug potency between susceptible and resistant isolates, with MOX demonstrating the highest efficacy. Resistance factors (RF) highlighted the substantial resistance of the isolate collected in a farm with EPR-treatment failure. The WMA effectively discriminated susceptible from resistant isolates in both C. elegans and H. contortus. Our findings demonstrate, for the first time, the relevance of WMA as a phenotypic assay for detecting ML resistance in nematodes by measuring their motility response. This research sheds light on a novel approach for monitoring drug resistance, vital for effective parasite management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.